Dementia with Lewy bodies: an update and outlook.
Tiago Fleming OuteiroDavid J KossDaniel ErskineLauren WalkerMarzena Kurzawa-AkanbiDavid BurnPaul DonaghyChristopher MorrisJohn-Paul TaylorAlan ThomasJohannes AttemsIan McKeithPublished in: Molecular neurodegeneration (2019)
Dementia with Lewy bodies (DLB) is an age-associated neurodegenerative disorder producing progressive cognitive decline that interferes with normal life and daily activities. Neuropathologically, DLB is characterised by the accumulation of aggregated α-synuclein protein in Lewy bodies and Lewy neurites, similar to Parkinson's disease (PD). Extrapyramidal motor features characteristic of PD, are common in DLB patients, but are not essential for the clinical diagnosis of DLB. Since many PD patients develop dementia as disease progresses, there has been controversy about the separation of DLB from PD dementia (PDD) and consensus reports have put forward guidelines to assist clinicians in the identification and management of both syndromes. Here, we present basic concepts and definitions, based on our current understanding, that should guide the community to address open questions that will, hopefully, lead us towards improved diagnosis and novel therapeutic strategies for DLB and other synucleinopathies.
Keyphrases
- mild cognitive impairment
- cognitive decline
- end stage renal disease
- chronic kidney disease
- parkinson disease
- ejection fraction
- cognitive impairment
- newly diagnosed
- prognostic factors
- multiple sclerosis
- peritoneal dialysis
- mental health
- patient reported outcomes
- physical activity
- clinical practice
- mass spectrometry
- liquid chromatography
- amino acid